Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Depreciation & Amortization (CF): 2009-2025

Historic Depreciation & Amortization (CF) for Lifecore Biomedical (LFCR) over the last 17 years, with May 2025 value amounting to $8.0 million.

  • Lifecore Biomedical's Depreciation & Amortization (CF) fell 4.97% to $1.9 million in Q2 2025 from the same period last year, while for May 2025 it was $8.0 million, marking a year-over-year increase of 0.92%. This contributed to the annual value of $8.0 million for FY2025, which is 0.92% up from last year.
  • Latest data reveals that Lifecore Biomedical reported Depreciation & Amortization (CF) of $8.0 million as of FY2025, which was up 0.92% from $8.0 million recorded in FY2024.
  • Over the past 5 years, Lifecore Biomedical's Depreciation & Amortization (CF) peaked at $19.9 million during FY2021, and registered a low of $8.0 million during FY2024.
  • Over the past 3 years, Lifecore Biomedical's median Depreciation & Amortization (CF) value was $8.0 million (recorded in 2025), while the average stood at $9.7 million.
  • As far as peak fluctuations go, Lifecore Biomedical's Depreciation & Amortization (CF) increased by 5.46% in 2021, and later slumped by 39.64% in 2024.
  • Lifecore Biomedical's Depreciation & Amortization (CF) (Yearly) stood at $19.9 million in 2021, then fell by 9.09% to $18.1 million in 2022, then dropped by 27.04% to $13.2 million in 2023, then tumbled by 39.64% to $8.0 million in 2024, then grew by 0.92% to $8.0 million in 2025.